▲全球视野 本土思考

政府已经批准了肾癌药物的仿制版本。

根据GlobalData的一份报告，印度昂贵的肿瘤药物的仿制药品牌的批准不仅将有助于降低此类药物的成本，而且还将在未来改善治疗的可及性和依从性。

最近，印度中央药品标准控制组织（Central Drugs Standard Control Organization）批准了舒尼替尼（Sunitinib）的几种通用版本来治疗肾癌。

GlobalData的药物分析师Krishna Srinivasaraghavan表示，昂贵的癌症诊断和治疗增加了印度的经济负担，因为自付费用的医疗费用中很大一部分是由患者承担的。

Srinivasaraghavan说：“因此，负担能力差和难以获得基本治疗导致该国较高的癌症死亡率。”

根据印度的国家癌症登记计划，到2020年，估计罹患癌症的人数约为225万人。同时，截至2月26日，印度共有1,351种通用药物可用于治疗各种癌症。

Launch of generic oncology drugs underway in India

The government has approved generic versions of a kidney cancer drug.

The approval of generic brands of expensive oncology drugs in India will not only help in reducing the cost of such drugs, but will also improve access and adherence to treatment in the future, according to a report from GlobalData.

Recently, India's Central Drugs Standard Control Organization has approved several generic versions of Sunitinib to treat kidney cancer.

Expensive cancer diagnostics and treatment add to the economic burden in India, as a huge part of out-of-pocket healthcare expenditure is borne by patients, said GlobalData's pharma analyst Krishna Srinivasaraghavan.

“As a result, non-affordability and limited access to basic treatment account for higher cancer mortality rate in the country,” Srinivasaraghavan said.

As per India's National Cancer Registry Programme, the estimated number of people living with cancer in 2020 was around 2.25 million. Meanwhile, 1,351 generic drugs are available in India for the treatment of different cancers as of 26 February.